TRACON Pharmaceuticals, Inc.

136 articles with TRACON Pharmaceuticals, Inc.

• TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

  1/19/2021

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, received notification that the New D

• TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

  1/6/2021

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corpora

• TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

  12/30/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, received notification that the Chine

• TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

  12/29/2020

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a securities purchase agreement with an existing investor to sell an a

• TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

  12/22/2020

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a securities purchase agreement

• TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialCompany Expects Interim Data in Mid-2021

  12/10/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced dosing of the first patient in the ENVASARC registration trial.

• TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

  11/23/2020

  TRACON Pharmaceuticals announced the publication of clinical data that provides molecular insight into TRC102’s mechanism of action and patient populations most likely to respond to treatment.

• TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

  11/16/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug applicatio

• TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/10/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the third quarter ended September 30, 2020. The Company will host a confer

• TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020

  11/3/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), announced today that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Tuesday, November 10, 2020.

• TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma

  10/26/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that the U.S. Food and Drug Administration (FDA) granted TRC102 orphan drug

• TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020

  9/21/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S

• TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO

• TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference

  9/3/2020

  TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the

• TRACON Pharmaceuticals Announces Additional $5.0 Million Private Placement

  8/31/2020

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S.,

• TRACON Pharmaceuticals Announces $5.0 Million Private Placement

  8/27/2020

  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a definitive securities purchase agreement with an institutional healt

• TRACON Pharmaceuticals Announces FDA Clearance of ENVASARC Pivotal TrialDosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S.

  8/17/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S.,

• TRACON Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/5/2020

  TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S.

• TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

  8/3/2020

  TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2

• TRACON to Report Second Quarter 2020 Financial Results and Company Highlights on August 5, 2020

  7/29/2020

  TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its second quarter 2020 financial and operating results after the close of U